Smith+Nephew signs distribution agreement with SI-BONE
MWN-AI** Summary
Smith+Nephew, a prominent global medical technology company, has announced a new distribution partnership with SI-BONE to incorporate SI-BONE's innovative iFuse TORQ portfolio into its offerings. This agreement aims to enhance Smith+Nephew's capabilities in percutaneous pelvic fracture fixation and bolster its presence in the trauma sector, which sees high surgical demand.
Scott Gunn, Vice President of Trauma, Extremities and Shoulder at Smith+Nephew, expressed enthusiasm for the partnership, emphasizing a mutual commitment to innovation and improved patient outcomes. The collaboration seeks to leverage SI-BONE's industry-leading technology and Smith+Nephew's established commercial channels to enhance access to advanced solutions, foster surgeon engagement, and stimulate sustainable growth.
The iFuse TORQ portfolio boasts breakthrough medical technology, including the iFuse TORQ TNT, which is specifically designed to cater to the anatomical and density requirements of the sacrum and ilium. Notably, iFuse TORQ TNT has obtained FDA Breakthrough Device Designation, recognizing its potential to improve pelvic fracture treatment effectiveness over traditional methods. Additionally, it qualifies for Medicare's New Technology Add-on Payment, which provides up to $4,136 in extra reimbursement per procedure, further incentivizing hospitals to adopt the technology.
By integrating the iFuse TORQ products into its portfolio, Smith+Nephew positions itself to better serve the needs of surgeons and patients in critical areas of trauma care. With record growth and a commitment to clinical excellence, this partnership enhances Smith+Nephew's mission of restoring lives through innovative medical solutions. As the company continues its growth trajectory, this collaboration marks a significant step toward optimizing its product portfolio and delivering long-term value in the medical technology landscape.
MWN-AI** Analysis
Smith+Nephew's recent distribution agreement with SI-BONE marks a strategic move to enhance its Trauma and Extremities portfolio, particularly through the innovative iFuse TORQ products. This collaboration underscores Smith+Nephew's disciplined approach to portfolio optimization, aimed at providing long-term value for both surgeons and patients in the medical technology sector.
The inclusion of the iFuse TORQ portfolio positions Smith+Nephew favorably within a high-frequency trauma market, notably enhancing their offerings in pelvic fracture fixation procedures. The iFuse TORQ TNT device stands out with its FDA Breakthrough Device Designation and the potential for additional reimbursement through Medicare, indicating significant market potential. With hospitals facing increasing pressures to optimize both outcomes and costs, the financial benefits associated with the iFuse TORQ products could drive adoption among healthcare providers.
From an investment perspective, this agreement may catalyze Smith+Nephew’s growth trajectory. The collaboration not only expands their product offering but also leverages SI-BONE’s expertise and existing sales channels. This strategy is likely to deepen surgeon engagement, potentially leading to an increase in surgical procedures utilizing these advanced solutions. Investors should watch for indications of early adoption rates and feedback from the surgical community, as these metrics could provide insights into future revenue growth.
Furthermore, Smith+Nephew's focus on innovative solutions aligns with market trends leaning towards personalized and effective treatment options in healthcare. As a constituent of the FTSE100 and a company with a strong global presence, Smith+Nephew's stock could likely benefit from this forward-thinking strategy, making it a potential buy for investors seeking exposure to the evolving medical technology landscape. Overall, this partnership represents a thoughtful alignment of capabilities that could yield competitive advantages for Smith+Nephew in the coming years.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Trauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced it has signed a distribution agreement with SI-BONE, focused on their innovative iFuse TORQ portfolio. This collaboration expands the Smith+Nephew portfolio offerings for percutaneous pelvic fracture fixation procedures and strengthens our position in high-frequency, high-impact trauma procedures.
“We’re incredibly excited to partner with SI-BONE,” said Scott Gunn, Vice President Trauma, Extremities and Shoulder. “This collaboration reflects a shared commitment to innovation, clinical excellence, and improving patient outcomes. By combining SI-BONE’s industry leadership with Smith+Nephew’s established commercial platform, we see a meaningful opportunity to expand access to differentiated solutions, deepen surgeon engagement, and drive sustainable growth.”
The iFuse TORQ portfolio includes iFuse TORQ TNT and iFuse TORQ implants, offering breakthrough solutions with indications for pelvic fracture fixation and fusion of the sacroiliac (SI) joint.123456
iFuse TORQ TNT is designed specifically to address the anatomical and bone density needs of the sacrum and ilium. iFuse TORQ TNT represents the next generation of technology for pelvic fracture fixation and SI joint fusion, providing a unique market advantage:
-
- FDA Breakthrough Device Designation (BDD)7: Recognized for its potential to provide more effective treatment of pelvic fractures compared to traditional cannulated screws.
-
- NTAP: Eligible for a Medicare New Technology Add-on Payment, which may provide up to $4,136 in additional reimbursement per procedure for hospitals using iFuse TORQ TNT.
Smith+Nephew will also have access to the broader iFuse TORQ portfolio alongside SI-BONE’s current sales channel, expanding the ability to serve surgeons and patients in this high-need area.
References:
1 iFuse TORQ TNT™ Implant System, 510(k) K241504
2 iFuse TORQ® Implant System, 510(k) K241574
3 iFuse TORQ® Implant System, 510(k) K231689
4 iFuse TORQ® Implant System, 510(k) K222605
5 iFuse TORQ® Implant System, 510(k) K213667
6 iFuse TORQ™ Implant System, 510(k) K203247
7 US Food and Drug Administration, Breakthrough Device Designation (BDD) Q231970
Media Enquiries
Gina Kamler +1 (901) 351-6991
Smith+Nephew gina.kamler@smith-nephew.com
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on LinkedIn, Instagram or Facebook.
About SI Bone
SI-BONE (NASDAQ: SIBN)?is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing a total of over 140,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 180 peer reviewed publications.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
FAQ**
How does the partnership between Smith & Nephew SNATS Inc. SNN and SI-BONE enhance the portfolio optimization strategy to improve outcomes for surgeons and patients in trauma and extremity procedures?
What specific innovations in the iFuse TORQ portfolio contribute to Smith & Nephew SNATS Inc. SNN's long-term value proposition for healthcare providers and patients?
In what ways does the collaboration between Smith & Nephew SNATS Inc. SNN and SI-BONE aim to deepen surgeon engagement in high-frequency trauma procedures?
How does receiving FDA Breakthrough Device Designation impact the growth expectations of Smith & Nephew SNATS Inc. SNN in the market for pelvic fracture fixation and SI joint fusion?
**MWN-AI FAQ is based on asking OpenAI questions about Smith & Nephew SNATS Inc. (NYSE: SNN).
NASDAQ: SNN
SNN Trading
-2.04% G/L:
$33.68 Last:
442,068 Volume:
$33.78 Open:
